Monika Nagy-Hulliger

Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study.

Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real-world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure-response...